GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » LT-Debt-to-Total-Asset

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.00). It may suggest that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.01 -

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=11.98/3146.461
=0.00

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=10.722/3069.177
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (HKSE:01349) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
HKSE:02877 HKSE:00460 HKSE:03613 HKSE:01681 HKSE:06185 HKSE:06896 HKSE:02186 HKSE:06600 HKSE:02348 HKSE:02552 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
688505:China
Address
No. 308, Cai Lun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Website
http://www.fd-zj.com
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Headlines

No Headlines